Influence of CYP2C8 and CYP2C9 polymorphisms on pharmacokinetic and pharmacodynamic parameters of racemic and enantiomeric forms of ibuprofen in healthy volunteers

Pharmacological Research

Volumn 58, Issue 1, 2008, Pages 77-84

  López Rodríguez, Rosario ^a   Novalbos, Jesús ^a   Gallego Sandín, Sonia ^a   Román Martínez, Manuel ^a   Torrado, Juan ^b   Gisbert, Javier P ^a,c   Abad Santos, Francisco ^a,c  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

CYP2C8; CYP2C9; Healthy volunteers; Ibuprofen

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; ENDOTHELIAL NITRIC OXIDE SYNTHASE; IBUPROFEN; INDUCIBLE NITRIC OXIDE SYNTHASE;

ADULT; ALLELE; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; ENANTIOMER; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE DRUG DOSE; SPAIN; STOMACH BIOPSY; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUNTEER; WESTERN BLOTTING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ALLELES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARYL HYDROCARBON HYDROXYLASES; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HUMANS; IBUPROFEN; MALE; METABOLIC CLEARANCE RATE; POLYMORPHISM, GENETIC; STEREOISOMERISM; YOUNG ADULT;

EID: 50649086561     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2008.07.004     Document Type: Article

References (43)

1. Davies N.M. Clinical pharmacokinetics of ibuprofen: the first 30 years. Clin Pharmacokinet 34 (1998) 101-154
2. Geisslinger G., Stock K.P., Loew D., Bach G.L., and Brune K. Variability in the stereoselective disposition of ibuprofen in patients with rheumatoid arthritis. Br J Clin Pharmacol 35 (1993) 603-607
3. Kaiser D.G., Vangiessen G.J., Reischer R.J., and Wechter W.J. Isomeric inversion of ibuprofen (R)-enantiomer in humans. J Pharm Sci 65 (1976) 269-273
4. Lee E.J., Williams K., Day R., Graham G., and Champion D. Stereoselective disposition of ibuprofen enantiomers in man. Br J Clin Pharmacol 19 (1985) 669-674
5. Day R.O., Williams K.M., Graham G.G., Lee E.J., Knihinicki R.D., and Champion G.D. Stereoselective disposition of ibuprofen enantiomers in synovial fluid. Clin Pharmacol Ther 43 (1988) 480-487
6. Avgerinos A., and Hutt A.J. Interindividual variability in the enantiomeric disposition of ibuprofen following the oral administration of the racemic drug to healthy volunteers. Chirality 2 (1990) 249-256
7. Reichel C., Brugger R., Bang H., Geisslinger G., and Brune K. Molecular cloning and expression of a 2-arylpropionylcoenzyme A epimerase: a key enzyme in the inversion metabolism of ibuprofen. Mol Pharmacol 51 (1997) 576-582
8. Leemann T.D., Transon C., Bonnabry P., and Dayer P. A major role for cytochrome P450TB (CYP2C subfamily) in the actions of non-steroidal antiinflammatory drugs. Drugs Exp Clin Res 19 (1993) 189-195
9. Hamman M.A., Thompson G.A., and Hall S.D. Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. Biochem Pharmacol 54 (1997) 33-41
10. Solus J.F., Arietta B.J., Harris J.R., Sexton D.P., Steward J.Q., McMunn C., et al. Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population. Pharmacogenomics 5 7 (2004) 895-931
11. Human Cytochrome P450 (CYP) Nomenclature Committee Website. Available from: URL: http://www.imm.ki.se/CYPalleles.htm.
12. Bahadur N., Leathart J.B., Mutch E., Steimel-Crespi D., Dunn S.A., Gilissen R., et al. CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6-alpha-hydroxylase activity in human liver microsomes. Biochem Pharmacol 64 (2002) 1579-1589
13. Cavaco I., Piedade R., Gil J.P., and Ribeiro V. CYP2C8 polymorphism among the Portuguese. Clin Chem Lab Med 44 2 (2006) 168-170
14. Soyama A., Saito Y., Komamura K., Ueno K., Kamakura S., Ozawa S., et al. Five novel single nucleotide polymorphisms in the CYP2C8 gene, one of which induces a frame-shift. Drug Metab Pharmacokinet 17 4 (2002) 374-377
15. Kirchheiner J., Meineke I., Freytag G., Meisel C., Roots I., and Brockmoller J. Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2. Clin Pharmacol Ther 72 (2002) 62-75
16. Martínez C., García-Martín E., Blanco G., Gamito F.J.G., Ladero J.M., and Agúndez J.A.G. The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects. Br J Clin Pharmacol 59 1 (2004) 62-68
17. García-Martín E., Martínez C., Tabarés B., Frías J., and Agúndez J.A.G. Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. Clin Pharmacol Ther 76 2 (2004) 119-127
18. García-Arieta A., Abad-Santos F., Rodríguez-Martínez M.A., Varas-Polo Y., Novalbos J., Laparidis N., et al. An eutomer/distomer ratio near unity does not justify non-enantiospecific assay methods in bioequivalence studies. Chirality 17 (2005) 470-475
19. Hawkey C.J., Hawthorne A.B., Hudson N., Cole A.T., Mahida Y.R., and Daneshmend T.K. Separation of the impairment of haemostasis by aspirin from mucosal injury in the human stomach. Clin Sci (Lond) 81 (1991) 565-573
20. Lanza F.L., Rack M.F., Simon T.J., Quan H., Bolognese J.A., Hoover M.E., et al. Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen. Aliment Pharmacol Ther 13 (1999) 761-767
21. Saano V., Paronen P., Peura P., and Vidgren M. Relative pharmacokinetics of three oral 400mg ibuprofen dosage forms in healthy volunteers. Int J Clin Pharm Ther Toxicol 29 (1991) 381-385
22. Fornasini G., Monti N., Brogin G., Gallina M., Eandi M., Persiani S., et al. Preliminary pharmacokinetic study of ibuprofen enantiomers after administration of a new oral formulation (ibuprofen arginine) to healthy male volunteers. Chirality 9 (1997) 297-302
23. Walser S., Hruby R., Hesse E., Heinzl H., and Mascher H. Preliminary toxicokinetic study with different crystal forms of S-(+)-ibuprofen (dexibuprofen) and R,S-ibuprofen in rats. Arzneimittelforschung 47 (1997) 750-754
24. Gallego-Sandín S., Novalbos J., Rosado A., Gisbert J.P., Gálvez-Múgica M.A., García A.G., et al. Effect of ibuprofen on cyclooxygenase and nitric oxide synthase of gastric mucosa: correlation with endoscopic lesions and adverse reactions. Digest Dis Sci 49 9 (2004) 1538-1544
25. Gisbert J.P., Abad-Santos F., Novalbos J., Khorrami S., Gallego-Sandín S., Rosado A., et al. Comparison of gastric endoscopic lesions and tolerability to ibuprofen and ibuprofen-arginate in healthy subjects. J Clin Gastroenterol 39 9 (2005) 834-835
26. Harris J.W., Rahman A., Kim B.R., Guengerich F.P., and Collins J.M. Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 54 (1994) 4026-4035
27. García-Martín E., Pizarro R.M., Martínez C., Gutierrez-Martín Y., Pérez G., Jover R., et al. Acquired resistance to the anticancer drug paclitaxel is associated with induction of cytochrome P450 2C8. Pharmacogenomics 7 4 (2006) 575-585
28. Tracy T.S., Korzekwa K.R., Gonzalez F.J., and Wainer I.W. Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil. Br J Clin Pharmacol 47 (1999) 545-552
29. Yamazaki H., Shibata A., Suzuki M., Nakajima M., Shimada N., Guengerich F.P., et al. Oxidation of troglitazone to a quinonetype metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes. Drug Metab Dispos 27 (1999) 1260-1266
30. Li X.Q., Bjorkman A., Andersson T.B., Ridderstrom M., and Masimirembwa C.M. Amodiaquine clearance and its metabolism to Ndesethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther 300 (2002) 399-407
31. Dorado P, Cavaco I, Cáceres MC, Piedade R, Ribeiro V, Llerena A. Relationship between CYP2C8 genotypes and diclofenac 5-hydroxylation in healthy Spanish volunteers. Eur J Clin Pharmacol; 2008 Jun 12 [Epub ahead of print].
32. Niemi M., Leathart J.B., Neuvonen M., Backman J.T., Daly A.K., and Neuvonen P.J. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clin Pharmacol Ther 74 (2003) 380-387
33. Evans A.M. Enantioselective pharmacodynamics and pharmacokinetics of chiral non-steroidal anti-inflammatory drugs. Eur J Clin Pharmacol 42 (1992) 237-256
34. Tornio A., Niemi M., Neuvonen P.J., and Backman J.T. Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen. Eur J Clin Pharmacol. 63 5 (2007) 463-469
35. Parikh S., Ouedraog J.B., Goldstein J.A., Rosenthal P.J., and Kroetz D.L. Amodiaquine metabolism is impaired by common polymorphisms in CYP2C8: implications for malaria treatment in Africa. Clin Pharmacol Ther 82 2 (2007) 197-203
36. Dai D., Zeldin D.Z., Blaisdell J.A., Chanas B., Coulter S.J., Ghanayem B.U., et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11 7 (2001) 597-607
37. Kirchheiner J., Thomas S., Bauer S., Tomalik-Scharte D., Hering U., Doroshyenko O., et al. Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype. Clin Pharmacol Ther 80 6 (2006) 657-667
38. Tornio A., Niemi M., Neuvonen P.J., and Backman J.T. Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone. Drug Metab Dispos 36 1 (2008) 73-80
39. Yasar U., Lundgren S., Eliasson E., Bennet A., Wiman B., de Faire U., et al. Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem Biophys Res Commun 299 1 (2002) 25-28
40. Cirino G. Nitric oxide releasing drugs: from bench to bedside. Dig Liver Dis 35 2 (2003) S2-S8
41. Cho C.H. Current roles of nitric oxide in gastrointestinal disorders. J Physiol Paris 95 1-6 (2001) 253-256
42. Martín M.J., Jiménez M.D., and Motilva V. New issues about nitric oxide and its effects on the gastrointestinal tract. Curr Pharm Des 7 10 (2001) 881-908
43. Villegas I., Martín M.J., La Casa C., Motilva V., and Alarcón de la Lastra C. Effects of meloxicam on oxygen radical generation in rat gastric mucosa. Inflamm Res 49 7 (2000) 361-366